source
- Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioThrough its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.
- Teva named stalking horse bidder to acquire BioXcel's neuroscience assets for $57.5 millionBioXcel Therapeutics, a Connecticut biotech focused on neuroscience, filed for Chapter 11 bankruptcy after running out of cash to fund operations through August. In the filing, the company selecte…